Literature DB >> 16778209

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.

Shinji Mizuarai1, Kazunori Yamanaka, Hidehito Kotani.   

Abstract

The tumor suppressor gene p53 is known to induce G1-S and G2-M cell cycle arrest and apoptosis by transactivating various wild-type (WT) p53 regulatory genes. Mutational inactivation of p53 is detected in more than half of human cancers, depriving the p53 protein of its tumor-suppressive functions. Recent studies have shown that mutant p53 provides tumor cells with gain-of-function properties, such as accelerated cell proliferation, increased metastasis, and apoptosis resistance. However, the mechanism underlying the elevated tumorigenicity by p53 mutation remains to be elucidated. In the present study, we showed that GEF-H1, a guanine exchange factor-H1 for RhoA, is transcriptionally activated by the induction of mutant p53 proteins, thereby accelerating tumor cell proliferation. Osteosarcoma U2OS cell lines, which express inducible p53 mutants (V157F, R175H, and R248Q), were established, and the expression profiles of each cell line were then analyzed to detect genes specifically induced by mutant p53. We identified GEF-H1 as one of the consensus genes whose expression was significantly induced by the three mutants. The GEF-H1 expression level strongly correlated with p53 status in a panel of 32 cancer cell lines, and GEF-H1 induction caused activation of RhoA. Furthermore, growth of mutant p53 cells was dependent on GEF-H1 expression, whereas that of WT p53 cells was not. These results suggest that increased GEF-H1 expression contributes to the tumor progression phenotype associated with the p53 mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778209     DOI: 10.1158/0008-5472.CAN-05-4629

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Transcriptional regulation of Rho GTPase signaling.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Transcription       Date:  2011 Sep-Oct

Review 2.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Authors:  Shinji Mizuarai; Hidehito Kotani
Journal:  Hum Genet       Date:  2010-10-26       Impact factor: 4.132

3.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Xin Wei Wang; Anuradha Budhu; Yun Hee Kim; So Mee Kwon; Zhao-You Tang; Zongtang Sun; Curtis C Harris; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2010-11-19       Impact factor: 22.682

Review 4.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

5.  Role of RhoA-specific guanine exchange factors in regulation of endomitosis in megakaryocytes.

Authors:  Yuan Gao; Elenoe Smith; Elmer Ker; Phil Campbell; Ee-chun Cheng; Siying Zou; Sharon Lin; Lin Wang; Stephanie Halene; Diane S Krause
Journal:  Dev Cell       Date:  2012-03-01       Impact factor: 12.270

6.  Association of FGD1 polymorphisms with early-onset breast cancer.

Authors:  Sarah Beasley; Phillip J Buckhaults; Nancy G Pedigo; Christopher L Farrell
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

Review 7.  The stiff RhoAd from mevalonate to mutant p53.

Authors:  Giovanni Sorrentino; Fiamma Mantovani; Giannino Del Sal
Journal:  Cell Death Differ       Date:  2018-03-06       Impact factor: 15.828

8.  Dipeptide analysis of p53 mutations and evolution of p53 family proteins.

Authors:  Qiang Huang; Long Yu; Arnold J Levine; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta       Date:  2013-04-10

Review 9.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

10.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.